@article{ETD,
      school = {Ph.D.},
      author = {Boniface, Christopher},
      url = {http://digitalcollections.ohsu.edu/record/10077},
      title = {Clinical and research applications of circulating tumor  DNA detection, monitoring, and dynamics in cancer patients},
      publisher = {Oregon Health and Science University},
      abstract = {Liquid biopsy provides a minimally-invasive alternative to  solid tissue biopsy for assessing tumor-derived molecules  such as circulating tumor DNA (ctDNA). Detection and  characterization of ctDNA in the blood shows promise in  early cancer screening and diagnosis, and has prognostic  value for risk-stratification at all stages of disease.  ctDNA can also be used for minimally-invasive tumor  genotyping, treatment monitoring, and pre-clinical  detection of minimal residual disease and recurrence.  Although once predicted as a panacea for these  applications, the clinical implementation of ctDNA assays  has met with significant technical hurdles. Moreover,  poorly-understood biological mechanisms and a lack of  standardized methods contribute to measurement variability.  The work that follows is intended to (1) highlight the need  for a deeper understanding of the biological underpinnings  of ctDNA release and kinetics, and (2) test the limits of  patient-specific and patient-agnostic ctDNA detection  technologies in the clinical setting.},
      number = {ETD},
      doi = {https://doi.org/10.6083/zk51vh59w},
      recid = {10077},
      address = {2023},
}